Products for Research Use Only

Allopurinol

CAT: 0804-HY-B0219-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0219-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect[1][2][3][4][5].
CAS Number
315-30-0
UNSPSC
12352005
Hazard Statement
H301, H317
Target
Xanthine Oxidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Allopurinol.html
Purity
99.97
Solubility
DMSO : 14 mg/mL (ultrasonic; warming) |H2O : 1 mg/mL (ultrasonic; adjust pH to 11 with NaOH)
Smiles
O=C1C2=C(NN=C2)N=CN1
Molecular Formula
C5H4N4O
Molecular Weight
136.11
Precautions
H301, H317
References & Citations
[1]Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58 (1) :87-114.|[2]Pfaller MA, et al. Antileishmanial effect of allopurinol. Antimicrob Agents Chemother. 1974;5 (5) :469-472. |[3]Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45 (3) :244-7.|[4]Schmidt AP, et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol. 2009 Jan;156 (1) :163-72.|[5]Sun Y, et al. Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. PLoS One. 2015 Apr 1;10 (4) :e0123649.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Adv Sci (Weinh) . 2024 Sep 3:e2400684.|Biomed Pharmacother. 2024 Jun 15:177:116859.|Cell Rep Med. 2024 Aug 20;5 (8) :101690.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Commun Biol. 2022 Jul 22;5 (1) :726.|Cytokine. 2023 Mar:163:156120.|Int J Mol Sci. 2025 Sep 16;26 (18) :8999.|J Biol Chem. 2021 Oct;297 (4) :101166.|J Ethnopharmacol. 2025 Jan 19:119365.|Mol Med. 2025 May 13;31 (1) :184.|Pharmaceuticals (Basel) . 2023 Feb 27;16 (3) :361.|Drug Deliv Transl Res. 2025 Oct 29.

Alternative Products